Search the GHTC website

Global health R&D delivers for Connecticut

US government investment in global health R&D has delivered

Amount
$87.2 million
to Connecticut research institutions
Jobs
850+ new jobs
for Connecticut
Connecticut's top USG-funded global health R&D institutions

Connecticut's top USG-funded global health R&D institutions

Yale University
$76.6 million
University of Connecticut (including Health Center and School of Medicine)
$9.9 million
Wesleyan University
$477 thousand
Connecticut Agricultural Experiment Station
$162 thousand
Connecticut industry in global health R&D

Connecticut industry in global health R&D

Achillion
Location(s): New Haven
Bristol-Myers Squibb
Location(s): Wallingford
Charles River Laboratories
Location(s): Lebanon, North Franklin, Preston, Storrs, Tafville, Voluntown, Willimantic
Gilead
Location(s): Branford
GSK
Location(s): Branford
Melinta Therapeutics
Location(s): New Haven
Pfizer
Location(s): Groton
Viiv Healthcare
Location(s): Branford

Connecticut's top areas of global health R&D by USG funding

5.4%
HIV/AIDS
8.5%
Malaria
5.8%
Tuberculosis
3.1%
Diarrheal diseases
20.1%
Salmonella infections
49.3%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
7.8%
Other
Global health R&D at work in Connecticut

Scientists at the University of Connecticut Center of Excellence for Vaccine Research in Storrs are working to develop a vaccine against Zika using a new method devised by the center to speed an early stage of vaccine development. Using this technique, researchers can create a prospective vaccine in a week, rather than months, allowing them to generate multiple variations of a vaccine quickly for further testing. Beyond contributing to the fight against Zika—a mosquito-borne virus linked to devastating birth defects—this technique holds promise to speed vaccine development against many other long-standing and emerging global health threats.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Dan Chang